GlassScriptPhysician profile
James S Leavitt
NPI 1598740557
$17,726.43
in general payments reported to CMS, 2019-2025
43 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,430 · 2020: $2,007 · 2021: $1,719 · 2022: $2,641 · 2023: $710 · 2024: $4,922 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Food and Beverage: $3,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Food and Beverage | $3,329.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $3,600.00 | 2024 | Fibroscan |
| Pentax of America, INC. | $3,126.24 | 2019-2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,649.00 | 2019-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $1,759.65 | 2021-2023 | Zeposia |
| Abbvie INC. | $1,537.40 | 2019-2025 | |
| Janssen Biotech, INC. | $987.99 | 2019-2023 | Stelara |
| Boston Scientific Corporation | $559.01 | 2019-2025 | Apollo Esg System, Resolution 360 Clip |
| Takeda Pharmaceuticals U.S.A., INC. | $467.61 | 2019-2024 | Eohilia, Entyvio |
| Medtronic, INC. | $364.69 | 2022-2025 | Gi Genius |
| Pfizer INC. | $331.22 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $306.78 | 2023-2025 | Voquezna |
| Daiichi Sankyo INC. | $167.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.53 | 2023-2025 | Cyltezo |
| Qol Medical, LLC | $153.97 | 2019 | |
| Intercept Pharmaceuticals, INC. | $139.58 | 2021-2024 | Ocaliva |
Show all 41 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Leavitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.